GlassScriptPhysician profile
Christopher Moyer
NPI 1417535410
$1,101.40
in general payments reported to CMS, 2019-2025
20 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.12 · 2023: $21.83 · 2024: $273 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156.84 | 2025 | |
| Lilly USA, LLC | $126.83 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $105.68 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $89.38 | 2024-2025 | Evenity, Prolia, Otezla |
| Lundbeck LLC | $87.96 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $77.01 | 2024-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $67.55 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.60 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.98 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $44.37 | 2024-2025 | Austedo Xr, Austedo Xr |
| Phathom Pharmaceuticals, INC. | $39.75 | 2025 | Voquezna |
| Organon LLC | $37.95 | 2022-2023 | Nexplanon |
| Kowa Pharmaceuticals America, INC. | $30.98 | 2024-2025 | Zoryve |
| Neurocrine Biosciences, INC. | $25.32 | 2025 | |
| Amneal Pharmaceuticals LLC | $22.56 | 2025 | Unithroid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $18.69 | 2024 | Tirosint, Licart |
| Axsome Therapeutics, INC. | $17.08 | 2025 | Symbravo |
| Astellas Pharma US INC | $16.39 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $15.63 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.85 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Moyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.